§ 27-18-49. Human leukocyte antigen testing.
(a) Every individual or group hospital or medical services plan contract delivered or
renewed in this state shall include coverage of the cost for human leukocyte antigen
testing, also referred to as histocompatibility locus antigen testing, for A, B, and
DR antigens for utilization in bone marrow transplantation. The testing must be performed
in a facility that is accredited by the American Association of Blood Banks or its
successors, and is licensed under the Clinical Laboratory Improvement Act, 42 U.S.C. § 263a, as it may be from time to time amended. At the time of the testing, the person being
Free access — add to your briefcase to read the full text and ask questions with AI
§ 27-18-49. Human leukocyte antigen testing.
(a) Every individual or group hospital or medical services plan contract delivered or
renewed in this state shall include coverage of the cost for human leukocyte antigen
testing, also referred to as histocompatibility locus antigen testing, for A, B, and
DR antigens for utilization in bone marrow transplantation. The testing must be performed
in a facility that is accredited by the American Association of Blood Banks or its
successors, and is licensed under the Clinical Laboratory Improvement Act, 42 U.S.C. § 263a, as it may be from time to time amended. At the time of the testing, the person being
tested must complete and sign an informed consent form that also authorizes the results
of the test to be used for participation in the National Marrow Donor Program. The
group hospital or medical services plan contract may limit each subscriber to one
of these testings per lifetime.
(b) This section shall not apply to insurance coverage providing benefits for: (1) Hospital
confinement indemnity; (2) Disability income; (3) Accident only; (4) Long-term care;
(5) Medicare supplement; (6) Limited benefit health; (7) Specified disease indemnity;
(8) Sickness or bodily injury or death by accident or both; and (9) Other limited
benefit policies.